Metoprolol succinate vs tartrate for tachycardia
Pro Research Analysisby 
Searched over 200M research papers
Metoprolol Succinate vs. Tartrate for Tachycardia: A Comparative Analysis
Introduction to Metoprolol Formulations
Metoprolol, a beta-blocker, is commonly prescribed for managing tachycardia, hypertension, and heart failure. It is available in two formulations: metoprolol succinate (a controlled-release form) and metoprolol tartrate (an immediate-release form). Understanding the differences in their pharmacokinetics, efficacy, and side effects is crucial for optimizing patient outcomes.
Pharmacokinetics and Pharmacodynamics
Steady-State Plasma Concentrations
Metoprolol succinate (CR) provides a more stable plasma concentration over a 24-hour period compared to metoprolol tartrate (conventional tablets) . This stability is associated with a lower peak plasma concentration and a higher concentration at the end of the dosing interval, which can be beneficial for maintaining consistent therapeutic effects throughout the day .
Beta-1 Blocking Effects
Both formulations effectively manage exercise-induced tachycardia, but metoprolol succinate maintains a more constant beta-1 blocking effect throughout the day . This can be particularly advantageous for patients requiring steady heart rate control.
Hemodynamic Effects in Heart Failure
Comparative Hemodynamic Impact
In patients with congestive heart failure, both metoprolol tartrate and succinate produce similar hemodynamic and clinical effects when administered at equivalent doses . However, metoprolol succinate may offer a more convenient dosing regimen (once daily) compared to metoprolol tartrate (twice daily), potentially improving patient adherence .
Adverse Hemodynamic Effects
Both formulations can cause adverse hemodynamic effects, such as decreased cardiac index and increased systemic vascular resistance, when readministered during chronic therapy . These effects are parallel in both drug groups, indicating no significant difference in safety profiles between the two formulations .
Efficacy in Tachyarrhythmias
Ventricular Tachyarrhythmias
Metoprolol has been shown to reduce the incidence of serious ventricular tachyarrhythmias, such as ventricular fibrillation, in patients with acute myocardial infarction . This protective effect underscores the importance of beta-blockers in managing life-threatening arrhythmias.
Inappropriate Sinus Tachycardia (IST)
In patients with IST, metoprolol succinate effectively reduces resting heart rate and is comparable to ivabradine in this regard . However, ivabradine may be better tolerated and more effective in reducing heart rate during daily activities and exercise, with fewer side effects like hypotension or bradycardia .
Tolerability and Safety
Long-Term Use
Metoprolol succinate is well tolerated over long-term use, with significant improvements in left ventricular ejection fraction and reductions in ventricular ectopic beats . This makes it a viable option for chronic management of heart failure and tachycardia.
Multifocal Atrial Tachycardia
Metoprolol, whether administered orally or intravenously, is effective in managing multifocal atrial tachycardia, significantly slowing heart rate and converting many patients to sinus rhythm without causing hemodynamic or respiratory deterioration .
Conclusion
Both metoprolol succinate and tartrate are effective in managing various forms of tachycardia, with each having unique advantages. Metoprolol succinate offers more stable plasma concentrations and convenient once-daily dosing, which can enhance patient adherence and provide consistent therapeutic effects. On the other hand, metoprolol tartrate, while requiring more frequent dosing, is equally effective in controlling heart rate and managing tachyarrhythmias. The choice between the two should be tailored to the patient's specific clinical needs, tolerability, and lifestyle considerations.
Sources and full results
Most relevant research papers on this topic